The leukemic stem cells in patients with chronic myeloid leukemia (CML) are well known to
be clinically resistant to conventional chemotherapy and may also be relatively resistant to …

Improvements in our understanding of the molecular basis of cancer have led to the clinical
development of protein kinase inhibitors, which target pivotal molecules involved in …

Background Although the vast majority of patients with chronic myeloid leukemia (CML)
respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de …

Mutations in the BCR/ABL kinase domain play a major role in resistance to imatinib
mesylate (IM). We report here that BCR/ABL kinase stimulates reactive oxygen species …

Self‐renewal of Bcr‐Abl+ chronic myeloid leukemia (CML) cells is sustained by a nuclear
activated serine/threonine‐(S/T) unphosphorylated β‐catenin. Although β‐catenin can be …

A high percentage of patients with BRAFV600E mutant melanomas respond to the selective
RAF inhibitor vemurafenib (RG7204, PLX4032) but resistance eventually emerges. To better …

As chronic myeloid leukemia (CML) progresses from the chronic phase to blast crisis, the
levels of BCR-ABL increase. In addition, blast-transformed leukemic cells display enhanced …

Genomic instability is a hallmark of chronic myeloid leukemia in chronic phase (CML-CP)
resulting in BCR-ABL1 mutations encoding resistance to tyrosine kinase inhibitors (TKIs) …

The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …

The Warburg effect refers to the phenomenon whereby cancer cells avidly take up glucose
and produce lactic acid under aerobic conditions. Although the molecular mechanisms …